Contents

FOREWORD **xx**
PREFACE **xxi**
EDITORS AND CONTRIBUTORS **xxii**

Introduction 1

1 Clinical Pharmacology of Antidiabetic Drugs 2
Andrea Llano, Gerry McKay, and Ken Paterson

Introduction **2**
Clinical Pharmacology **3**
Introduction **3**
Pharmacodynamics **3**
Action on a Receptor **3**
Action on an Enzyme **4**
Membrane Channels **4**
Cytotoxic **4**
Dose–Response Relationship **4**
Pharmacokinetics **5**
Absorption **5**
Distribution/Plasma Protein Binding **5**
Clearance **6**
Drug Metabolism and Elimination **6**
Enzyme Induction and Inhibition **7**
Renal Excretion **7**
Drug Development and Clinical Trials **7**
Introduction **7**
Preclinical Development **8**
Regulatory Approval **9**
Clinical Trials **11**
Microdosing **11**
Phase 1 Trials **11**
Phase 2 Trials **11**
Phase 3 Trials **11**
Phase 4 Trials **12**
Drug Licensing of Antidiabetic Drugs **12**
Cardiovascular Outcome Trials **12**
Marketing Authorisation **14**
Development and Licensing of Insulin **14**
Insulin Regulatory Approval **14**

Development and Approval of Biosimilar Insulin **16**
Introduction **16**
Insulin Production **16**
Biosimilar vs. Generic Drugs **17**
Regulatory Considerations for Biosimilars **17**
Safety of Biosimilars **18**
Interchangeability and Substitution **18**
Prescribing Considerations for Biosimilars **18**
Pharmacovigilance **19**
Passive Pharmacovigilance **19**
Active Pharmacovigilance **20**
Pharmacoeconomics **21**
Introduction **21**
Utility Values **23**
Health Economic Modelling **23**
Sensitivity Analysis **24**
Discounting **25**
Indirect Comparison and Network Meta-analysis **25**
Future Developments in Diabetes Clinical Pharmacology **26**
Drug Development **26**
Pharmacovigilance **27**
Pharmacoeconomics **27**

2 Metformin 30
Joseph Timmons and James Boyle

Introduction **30**
History of Biguanides **31**
Phenformin and Lactic Acidosis **31**
Pharmacology **32**
Mechanism of Action **32**
Inhibition of Hepatic Glucose Production **33**
Reduced Insulin Resistance **34**
Intestinal Effects **34**
Pharmacokinetics **35**
Prescribing in Renal Impairment **35**
Prescribing in Liver Disease **35**
Prescribing in Heart Failure **35**
Prescribing in Pregnancy **35**
Glycaemic Efficacy **36**
Safety and Side Effects **37**
Lactic Acidosis **37**
Outcome Trials **38**

Cardiovascular Outcome Trials **38**
UKPDS **38**
HOME Study **39**
SPREAD-DIMCAD **41**
Renal Effects **42**
Prevention of Type 2 Diabetes **42**
DPP **42**
IDPP **44**
CANOE **44**
Metformin in Type 1 Diabetes **45**
REMOVAL **45**
Place of Metformin in Current and Future Practice **46**

3 Sulfonylureas and Meglitinides 49
Joseph Timmons and James Boyle

Introduction **49**
History of Sulfonylureas **50**
Pharmacology **51**
Insulin Secretion from Beta Cells **51**
Mechanism of Action **51**
Insulin Secretion **51**
Extra-pancreatic Actions **51**
Pharmacokinetics **52**
Gliclazide **52**
Glimepiride **53**
Glycaemic Efficacy **53**
ADOPT **53**
UKPDS **54**
GRADE Study **54**
Safety and Side Effects **55**
Weight Gain **55**
Hypoglycaemia **55**
Other Side Effects **55**
Outcome Trials **56**
Cardiovascular Safety and Sulfonylureas **56**
UGDP **56**
UKPDS **57**
ADVANCE **59**
CAROLINA **60**
TOSCA.IT **60**
Meglitinides **61**
Nateglinide **61**

Repaglinide **61**
Outcome Trials **62**
NAVIGATOR **62**
Place of Sulfonylureas and Meglitinides in Current and Future Practice **65**

4 DPP-4 Inhibitors 67
Sharon Mackin and Gemma Currie

Introduction **67**
Pharmacology **68**
Structure and Function of Dipeptidyl Peptidase-4 **68**
Mechanism of Action **68**
Pharmacodynamics and Pharmacokinetics **69**
Sitagliptin **69**
Saxagliptin **70**
Vildagliptin **71**
Alogliptin **72**
Linagliptin **73**
Other DPP-4 Inhibitors **73**
Glycaemic Efficacy **75**
VERIFY **75**
GRADE **79**
Safety and Side Effects **79**
Side Effects **80**
Pancreatitis and Pancreatic Cancer **80**
Hepatic Side Effects of Alogliptin **82**
Outcome Trials **82**
Cardiovascular Outcome Trials **82**
SAVOR-TIMI 53 **84**
EXAMINE **85**
TECOS **86**
CARMELINA and CAROLINA **87**
Vildagliptin Meta-analysis **88**
Summary of Cardiovascular Outcome Trials **89**
Renal Outcomes **89**
Saxagliptin **89**
Alogliptin **90**
Sitagliptin **90**
Linagliptin **90**
Summary of Renal Effects **91**
The Place of DPP-4 Inhibitors in Current and Future Practice **91**

5 SGLT2 Inhibitors 95
Miles Fisher, Andrea Llano, and Gerry McKay

Introduction **96**
Pharmacology **96**
Physiology of Sodium-dependent Glucose Transporters **96**
Mechanism of Action **97**
Pharmacodynamics and Pharmacokinetics **97**
Dapagliflozin **97**
Canagliflozin **98**
Empagliflozin **99**
Ertugliflozin **99**
Sotagliflozin **100**
Other SGLT2 Inhibitors **100**
Glycaemic Efficacy **100**
Comparisons of SGLT2 Inhibitors with GLP-1 Receptor Agonists **101**
Additional Effects of SGLT2 Inhibitors **102**
Body Weight **102**
Blood Pressure **103**
Side Effects and Safety **103**
Genitourinary Infections **103**
Diabetic Ketoacidosis **103**
Amputation **104**
Other Adverse Effects **105**
Outcome Trials **105**
Cardiovascular Outcome Trials in Diabetes **105**
EMPA-REG OUTCOME **105**
The CANVAS Program **108**
DECLARE-TIMI 58 **108**
VERTIS CV **109**
Meta-analysis of Cardiovascular Outcome Trials **109**
Real-world Evidence of Cardiovascular Benefits **109**
Renal Outcome Trials **110**
CREDENCE **111**
DAPA-CKD **112**
SCORED **113**
Empagliflozin **113**
Ertugliflozin **114**
Meta-analysis of Renal Outcomes **114**
Real-world Evidence of Renal Benefit **115**
Heart Failure Outcome Trials **116**

DAPA-HF **116**
The EMPEROR Trials Program **116**
SOLOIST-WHF **118**
Canagliflozin and Ertugliflozin **118**
Meta-analysis of DAPA-HF and EMPEROR-Reduced **118**
SGLT2 Inhibitors in Type 1 Diabetes **119**
Dapagliflozin in Type 1 Diabetes **119**
Sotagliflozin in Type 1 Diabetes **121**
Efficacy and Safety of Other SGLT2 Inhibitors in Type 1 Diabetes **121**
Diabetic Ketoacidosis **122**
Regulatory Approval in Type 1 Diabetes **123**
Use of SGLT2 Inhibitors in Other Diseases **123**
DARE-19 **123**
Place of SGLT2 Inhibitors in Current and Future Practice **124**
Type 2 Diabetes **124**
Chronic Kidney Disease and Heart Failure **124**
Type 1 Diabetes **125**

6 GLP-1 Receptor Agonists 130
Catherine Russell and John Petrie

Introduction **130**
Pharmacology **131**
Glucagon-like Peptide-1 and the Incretin Effect **131**
Mechanism of Action **131**
Pancreatic Actions **131**
Extra-pancreatic Actions **131**
Pharmacodynamics and Pharmacokinetics **132**
Exenatide **133**
Lixisenatide **134**
Liraglutide **134**
Dulaglutide **135**
Semaglutide **135**
Other GLP-1 Receptor Agonists **136**
Glycaemic Efficacy and Effect on Weight **137**
Comparisons within Class **137**
Comparisons with Other Antidiabetic Drugs **139**
DPP-4 Inhibitors **139**
SGLT2 Inhibitors **139**
Insulin **139**
Other Antidiabetic Drugs **140**
Efficacy of Combinations of GLP-1 Receptor Agonists with Insulin **140**
Other Effects of GLP-1 Receptor Agonists **141**

Cardiovascular System **141**
Lipids **142**
Side Effects and Safety **142**
Side Effects **142**
Safety **142**
Thyroid Cancer **142**
Pancreatitis and Pancreatic Cancer **143**
Cholelithiasis **143**
Outcome Trials **143**
Cardiovascular Outcome Trials **143**
ELIXA **143**
LEADER **145**
SUSTAIN-6 **146**
EXSCEL **147**
REWIND **148**
Harmony Outcomes **149**
PIONEER 6 **149**
AMPLITUDE-O **150**
Meta-analysis of Cardiovascular Outcome Trials **151**
Summary of Cardiovascular Outcome Trials **151**
Renal Outcomes **152**
Renal Outcomes from Cardiovascular Outcome Trials **152**
Meta-analysis of Renal Outcomes from Cardiovascular Outcome Trials **153**
Use of GLP-1 Receptor Agonists in Other Diseases **153**
Overweight and Obesity **153**
Nonalcoholic Fatty Liver Disease **155**
Place of GLP-1 Receptor Agonists in Current and Future Practice **155**

7 Animal and Human Insulins 161
Ken Paterson

Introduction **161**
Insulin Structure **161**
Insulin Receptors **162**
Insulin Physiology **163**
Production and Pharmacokinetic Modifications **165**
Improved Purification **165**
Time Action Prolongation **166**
Insulin Zinc Suspension **166**
Protamine Zinc Insulin **167**
Isophane or Neutral Protamine Hagedorn Insulin **167**
Biphasic Insulins **168**
Unified Formulation **168**

Sources of Insulin **169**
Beef Insulin **169**
Pork Insulin **169**
Human Insulin **169**
Hypoglycaemia and Human Insulin **170**
Limitations of Older Insulins **170**
Short-acting Insulins **171**
Intermediate and Long-acting Insulins **171**
Time–Action Profile **171**
Morning (Fasting) Hyperglycaemia **172**
Variability **173**
Intensified Insulin Therapy **173**
DCCT and EDIC **173**
UKPDS **174**
Side Effects of Intensified Insulin Therapy **175**
Hypoglycaemia **175**
Weight Gain **176**
Place of Human Insulin in Current and Future Therapy **176**
Insulin Therapy in Type 1 Diabetes **176**
Insulin Therapy in Type 2 Diabetes **177**

8 Short-acting Insulin Analogues 179
Kate Hughes and Gerry McKay

Introduction **179**
Factors Affecting Absorption and Metabolism of Short-acting Insulin **180**
Manufacturing Insulin Analogues **180**
Short-acting Insulin Analogues **182**
Insulin Lispro **182**
Insulin Aspart **183**
Insulin Glulisine **184**
Meta-analysis of Short-acting Insulin Analogues **185**
Biosimilar Short-acting Insulin Analogues **186**
Second-generation Ultrafast-acting Insulin Analogues **186**
Fast-acting Insulin Aspart **186**
Ultra-rapid Insulin Lispro **188**
Other Attempts to Improve Insulin Absorption and Inhaled Insulin **189**
Technosphere Inhaled Insulin **190**
Place of Short-acting Insulin Analogues in Current and Future Practice **190**
Intensive Insulin Therapy **190**
Structured Education **191**
Alternative Routes of Insulin Delivery **191**

9 Long-acting Insulin Analogues 194
Robert Lindsay

Introduction **195**
Older Strategies to Extend the Action of Insulin **195**
Factors Affecting the Absorption and Action of Insulin **195**
Development of Long-acting Insulin Analogues **196**
Strategies to Modify the Action of Long-acting Insulin Analogues **196**
Long-acting Insulin Analogues **197**
Insulin Glargine **197**
Glycaemic Efficacy and Risk of Hypoglycaemia with Glargine **198**
ORIGIN **198**
Insulin Detemir **199**
Glycaemic Efficacy and Risk of Hypoglycaemia with Detemir **200**
4-T **201**
Insulin Degludec **201**
Glycaemic Efficacy and Risk of Hypoglycaemia with Degludec **201**
DEVOTE **202**
U300 Glargine **203**
Glycaemic Efficacy and Risk of Hypoglycaemia with U300 Glargine **203**
Biosimilar Long-acting Insulin Analogues **205**
Other Long-acting Insulin Analogues **205**
Combinations of Long- and Short-acting Insulin Analogues **206**
Meta-analysis of Glycaemic Efficacy of Long-acting Insulin Analogues **207**
Type 1 Diabetes **207**
Type 2 Diabetes **207**
Safety of Long-acting Insulin Analogues **209**
The Place of Long-acting Insulin Analogues in Current and Future Practice **209**
Advantages of Insulin Analogues **209**
Patterns of Insulin Administration **210**
Future Long-acting Insulin Analogues **210**

10 Devices 214
David Carty

Introduction **214**
Insulin Pens **215**
History **215**
Modern Insulin Pens **215**
Insulin Pumps **215**
History **215**
Modern Insulin Pumps **216**

Glycaemic Efficacy of Insulin Pumps **216**
Safety of Insulin Pumps **217**
Potential Disadvantages of Pump Therapy **217**
Self-monitoring of Blood Glucose **218**
Blood Glucose Monitors **218**
Continuous Glucose Monitoring **218**
Intermittently Scanned (Flash) Continuous Glucose Monitoring **220**
Real-time Continuous Glucose Monitoring **221**
Accuracy of Continuous Glucose Monitoring **221**
Ambulatory Glucose Profiles **221**
Time in Range **221**
Efficacy of Continuous Glucose Monitoring **223**
Linkage of Continuous Glucose Monitoring to Insulin Pumps **223**
Low-glucose Suspend **223**
Hybrid Closed Loop **224**
Efficacy of Closed Loop Systems **225**
DIY Closed Loop **225**
Guidelines on the Use of Devices **225**
Insulin Pumps **225**
Continuous Glucose Monitoring **226**
Place of Devices in Current and Future Practice **227**

11 Acarbose and Alpha Glucosidase Inhibitors 229
Miles Fisher

Introduction **229**
Pharmacology **230**
Mechanism of Action **230**
Acarbose **230**
Other Alpha Glucosidase Inhibitors **231**
Glycaemic Efficacy **231**
Safety and Side Effects **232**
Outcome Trials **232**
Prevention of Type 2 Diabetes **232**
STOP-NIDDM **232**
Voglibose Ph-3 Study **234**
Cardiovascular Outcome Trials **235**
Meta-analysis of Cardiovascular Events with Acarbose **235**
ACE **236**
Meta-analysis of Cardiovascular Events with Alpha Glucosidase Inhibitors **237**
Place of Alpha Glucosidase Inhibitors in Current and Future Practice **237**

12 Glitazones and Glitazars 239
Miles Fisher

Introduction **239**
Pharmacology **240**
Mechanism of Action **240**
Pharmacokinetics **241**
Pioglitazone **241**
Glycaemic Efficacy **241**
ADOPT **241**
Other Effects of Glitazones **242**
Safety and Side Effects **242**
Side Effects **242**
Safety **243**
Cardiovascular Safety **243**
Heart Failure **244**
Bone Fractures **244**
Bladder Cancer **245**
Outcome Trials **245**
Cardiovascular Outcome Trials **245**
RECORD **245**
TIDE **247**
PROactive **247**
IRIS **249**
TOSCA.IT **250**
Prevention of Type 2 Diabetes **251**
DREAM **251**
Other Trials on the Prevention of Diabetes **251**
Glitazars **252**
Aleglitazar **253**
Saroglitazar **253**
Place of Glitazones and in Current and Future Practice **253**
Type 2 Diabetes **253**
Prevention of Diabetes **254**

13 Other Antidiabetic Drugs 257
Maroria Oroko, Andrea Llano, and Miles Fisher

Introduction **257**
Pramlintide **258**
Pharmacology **258**
Glycaemic Efficacy **259**
Efficacy in Type 1 Diabetes **259**

Efficacy in Type 2 Diabetes **259**
Safety **260**
Colesevelam **260**
Pharmacology **260**
Glycaemic Efficacy **261**
Cardiovascular Safety **262**
Bromocriptine **262**
Pharmacology **262**
Glycaemic Efficacy **263**
Cylcoset Safety Trial **263**
Hydroxychloroquine **264**
Pharmacology **265**
Glycaemic Efficacy **265**
Antiobesity Drugs **265**
Orlistat **266**
Pharmacology **266**
Glycaemic Efficacy **266**
XENDOS **267**
Naltrexone/Bupropion **268**
Pharmacology **268**
Efficacy **268**
Cardiovascular Safety **268**
Phentermine and Phentermine/Topiramate **269**
Pharmacology **269**
Efficacy **269**
Cardiovascular Safety **270**
Place of Other Drugs in Current and Future Practice **270**
Type 1 Diabetes **270**
Type 2 Diabetes **271**

14 Future Antidiabetic Drugs 274
Emma Johns and Miles Fisher

Introduction **274**
Dual and Triple Agonists **275**
Physiology **275**
GLP-1 **275**
GIP **275**
Glucagon **277**
Pharmacology of Multiagonist Therapies **277**
GLP-1/GIP Receptor Dual Agonists **278**
Tirzepatide **278**
NNC0090-2746 **285**

GLP-1/Glucagon Receptor Dual Agonists **285**
Cotadutide **285**
Bamadutide **286**
GLP-1/Glucagon Receptor Dual Agonists in Non-alcoholic Fatty Liver Disease **287**
Triple Agonists **287**
Imeglimin **288**
Pharmacology **288**
Mechanism of Action **288**
Pharmacokinetics **288**
Glycaemic Efficacy and Safety **288**
Regulatory Status **290**
Place of New Antidiabetic Drugs in Future Practice **291**

15 Guidelines on Antidiabetic Drugs 294
Miles Fisher and Russell Drummond

Introduction **295**
Evidence-based Guidelines **295**
Consensus Reports **295**
Common Approaches and HbA1c Targets **295**
Guidelines on the Use of Antidiabetic Drugs in Type 2 Diabetes **298**
NICE **298**
SIGN **300**
ICGP **300**
EASD and ADA Consensus Reports **302**
ESC **305**
IDF **307**
Guidelines on the Management of Type 1 Diabetes **308**
NICE **308**
SIGN **308**
ADA **310**
ADA/ESD Consensus Report on the Management of Type 1 Diabetes in Adults **310**
Special Patient Groups **311**
Use of Antidiabetic Drugs in Pregnancy **311**
Use of Antidiabetic Drugs in Patients with Kidney Disease **313**
KDIGO **313**
ABCD **314**
Use of Antidiabetic Drugs during Ramadan **315**
Use of Antidiabetic Drugs in Under-resourced Countries **316**
Place of Guidelines in Current and Future Practice **318**

16 Prescribing Antidiabetic Drugs 322
Andrea Llano, Gerry McKay, Frances McManus, Catriona McClements, Joyce McKenzie, and Deborah Morrison

Introduction **322**
Why Prescribe? **323**
Therapeutic Inertia **323**
Introduction **323**
Causes of Therapeutic Inertia **324**
Clinician-related Factors **324**
Patient-related Factors **325**
Healthcare System Factors **326**
Overcoming Inertia **326**
Polypharmacy **326**
Introduction **326**
Detecting and Managing Polypharmacy **327**
Nonadherence **329**
Introduction **329**
Improving Adherence **330**
The Patient with Problematic Hypoglycaemia **330**
Introduction **330**
Problematic Hypoglycaemia **331**
Management of Problematic Hypoglycaemia **331**
Identify and Characterise Hypoglycaemia **332**
Review Risk Factors for Problematic Hypoglycaemia **332**
Review Patient Education and Behaviour **332**
Review Insulin **333**
Prescribing in Renal Impairment **333**
Introduction **333**
Reduced Absorption **335**
Increased Bioavailability **335**
Reduced Renal Clearance **335**
Metformin **335**
Pioglitazone **335**
Acarbose **336**
Sulfonylureas and Meglitinides **336**
Incretin-based Therapies **336**
SGLT2 Inhibitors **336**
Insulin **336**
Prescribing in Liver Disease **337**
Introduction **337**
Liver Disease and Diabetes **337**
Reduced Drug Absorption **338**

Increased Volume of Distribution **339**
Altered Protein Binding **339**
Reduced Metabolism **339**
Hepatic Blood Flow **339**
Reduced Excretion **339**
Metformin **339**
Pioglitazone **339**
Sulfonylureas and Meglitinides **339**
Incretin-based Therapies **340**
SGLT2 Inhibitors **340**
Insulin **340**
Acarbose **340**
Prescribing in Cardiovascular Disease **340**
Diabetes and Coronary Artery Disease **340**
Glycaemic Control **342**
Choosing Antidiabetic Drugs with Cardiovascular Benefit **345**
Management of Other Cardiovascular Risk Factors **345**
Blood Pressure Management **345**
Lipid Management **345**
Antiplatelet Therapy **345**
Acute Coronary Syndromes **345**
Diabetes and Heart Failure **346**
Pioglitazone **346**
Saxagliptin **346**
GLP-1 Receptor Agonists **346**
SGLT2 Inhibitors **347**
Prescribing in Pregnancy **347**
Introduction **347**
Antidiabetic Drugs in Pregnancy **347**
Other Drugs Used in Pregnancy **348**
Breastfeeding **348**
Prescribing in the Young **348**
Prescribing in the Elderly **349**
Introduction **349**
Hypoglycaemia in the Elderly **350**
The Patient with Type 1 Diabetes: a Therapeutic Journey (an Illustrative Case) **350**
The Patient with Type 2 Diabetes: a Therapeutic Journey (an Illustrative Case) **351**
Future Developments in Prescribing in Diabetes **353**

APPENDIX **357**
INDEX **359**